Market cap
$134 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | 49.78 | 61.84 | 35.52 | -- | -- |
| Net Profit | 23.96 | 60.59 | -28.97 | -- | -- |
| EPS | 24.52 | 62.24 | -26.56 | -- | -- |
| Book Value | -- | -- | -28.86 | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-22 | Dec-21 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -- | -- | -57.38 | -41.86 | -30.44 |
| Return on Capital
| -- | -- | -- | -41.86 | -30.44 |
| Return on Assets
| -- | -- | -47.63 | -39.28 | -27.65 |
| Debt to Equity (x)
| -- | -- | 0.00 | -- | -- |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Pardes Biosciences Inc (PRDS)
|
--
|
-41.86
|
-30.44
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-57.38
Lower than Peers by 17.09
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Pardes Biosciences Inc (PRDS)
|
-57.38
|
-41.86
|
-30.44
|
--
|
--
|
|
Peer Median
|
-40.29
|
--
|
--
|
--
|
--
|
ROA
-47.63
Lower than Peers by 16.79
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Pardes Biosciences Inc (PRDS)
|
-47.63
|
-39.28
|
-27.65
|
--
|
--
|
|
Peer Median
|
-30.84
|
--
|
--
|
--
|
--
|
EBIT Growth
35.52
Higher than Peers by 36.48
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Pardes Biosciences Inc (PRDS)
|
35.52
|
-159.35
|
-503.68
|
--
|
--
|
|
Peer Median
|
-0.95
|
--
|
--
|
--
|
--
|
Net Profit Growth
-28.97
Lower than Peers by 21.78
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Pardes Biosciences Inc (PRDS)
|
-28.97
|
-142.43
|
--
|
--
|
--
|
|
Peer Median
|
-7.19
|
--
|
--
|
--
|
--
|
EPS Growth
-26.56
Lower than Peers by 41.00
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Pardes Biosciences Inc (PRDS)
|
-26.56
|
-1.55
|
--
|
--
|
--
|
|
Peer Median
|
14.43
|
--
|
--
|
--
|
--
|
Book Value Growth
-33.13
Lower than Peers by 22.67
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Pardes Biosciences Inc (PRDS)
|
-33.13
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.46
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Pardes Biosciences Inc (PRDS)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Pardes Biosciences Inc (PRDS)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
81.72
Higher than Peers by 75.92
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Pardes Biosciences Inc (PRDS)
|
81.72
|
9.81
|
30.70
|
0.22
|
--
|
|
Peer Median
|
5.80
|
--
|
--
|
--
|
--
|
Quick Ratio
81.72
Higher than Peers by 76.03
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Pardes Biosciences Inc (PRDS)
|
81.72
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.69
|
--
|
--
|
--
|
--
|
Interest Coverage
-22.81
Lower than Peers by 20.72
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Pardes Biosciences Inc (PRDS)
|
-22.81
|
-31.36
|
-1,282.93
|
--
|
--
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Pardes Biosciences Inc (PRDS)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.07
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Pardes Biosciences Inc (PRDS)
|
--
|
-1.07
|
-26.49
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
0.37
Lower than Peers by 4.98
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Pardes Biosciences Inc (PRDS)
|
0.37
|
0.56
|
3.83
|
--
|
--
|
|
Peer Median
|
5.35
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Pardes Biosciences Inc (PRDS)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
1.53
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Pardes Biosciences Inc (PRDS)
|
1.53
|
1.04
|
19.55
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
134
Lower than Peers by 14
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Pardes Biosciences Inc (PRDS)
|
134
|
--
|
--
|
--
|
--
|
|
Peer Median
|
147
|
--
|
--
|
--
|
--
|